Key facts
- It has raised $5.6M; the latest was Later Stage VC ($5.6M) in Jul 2025.
- Notable investors include CMG SDIC Fund, Lotus Lake Ventures, Ciit Asset Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Tuoxin Tiancheng
- ·The full record, as it builds
Funding rounds
No funding rounds for Tuoxin Tiancheng are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tuoxin Tiancheng
Manufacturer of cell-based therapeutic technologies intended for oncology and immunotherapy applications. The company offers proprietary CAR-T engineering methods, multi-target antibody development, and clinical-grade production capabilities, serving biomedical research institutions and healthcare providers to access advanced immunotherapeutic solutions with enhanced specificity, scalability, and regulatory compliance for translational and clinical use.
- Sector
- Healthcare
- HQ
- Fuzhou, China
- Founded
- 2017
- Website
- tcelltech.cn/
- Ownership
- Privately Held (backing)
Tuoxin Tiancheng doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tuoxin Tiancheng shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tuoxin Tiancheng in its N-PORT filings yet. We sweep new filings monthly.